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ABSTRACT
Objectives: Urinary tract infections (UTIs) account for
over 30% of healthcare-associated infections. The aim
of this study was to determine healthcare-associated
UTI (HAUTI) and catheter-associated UTI (CAUTI) point
prevalence in six Australian hospitals to inform a
national point prevalence process and compare two
internationally accepted HAUTI definitions. We also
described the level and comprehensiveness of clinical
record documentation, microbiology laboratory and
coding data at identifying HAUTIs and CAUTIs.
Setting: Data were collected from three public and
three private Australian hospitals over the first
6 months of 2013.
Participants: A total of 1109 patients were surveyed.
Records of patients of all ages, hospitalised on the day of
the point prevalence at the study sites, were eligible for
inclusion. Outpatients, patients in adult mental health
units, patients categorised as maintenance care type
(ie, patients waiting to be transferred to a long-term care
facility) and those in the emergency department during
the duration of the survey were excluded.
Outcome measures: The primary outcome measures
were the HAUTI and CAUTI point prevalence.
Results: Overall HAUTI and CAUTI prevalence was
1.4% (15/1109) and 0.9% (10/1109), respectively.
Staphylococcus aureus and Candida species were the
most common pathogens. One-quarter (26.3%) of
patients had a urinary catheter and fewer than half had
appropriate documentation. Eight of the 15 patients
ascertained to have a HAUTI based on clinical records
(6 being CAUTI) were coded by the medical records
department with an International Classification of
Diseases (ICD)-10 code for UTI diagnosis. The Health
Protection Agency Surveillance definition had a positive
predictive value of 91.67% (CI 64.61 to 98.51)
compared against the Centers for Disease Control and
Prevention definition.
Conclusions: These study results provide a
foundation for a national Australian point prevalence
study and inform the development and implementation
of targeted healthcare-associated infection surveillance
more broadly.
BACKGROUND
Healthcare-associated infections (HAIs) have
considerable medical consequences and
pose a significant problem for patient safety.1
A recent systematic review and meta-analysis
of 220 international articles indicated that
the prevalence and incidence of HAIs is 10%
and 7% per 100 patients, respectively.2
Further, the prevalence of infected patients
is 11% per 100 patients.2 Fifty per cent of the
reviewed prevalence studies stated magni-
tudes of infected patients higher than 10%
per 100 patients.2 The Centers for Disease
Control and Prevention estimates that 1.7
million people develop HAIs and 100 000
people die of HAI-related complications
each year in the USA.3 The first European
Union-wide Point Prevalence Survey (PPS) of
HAIs and antimicrobial use in hospitals con-
ducted in 2011–2012 estimated that on any
given day, about 80 000 patients have at least
one HAI, that is, 1 in 18 patients in a
European hospital has a HAI.4 The studies
support the view that HAIs are the most
common complication of hospitalisation.
This concept is not new, as demonstrated in
a landmark paper “To Err is Human:
Building a Safer Health System” published in
1999 by the Institute of Medicine (IOM).5
Strengths and limitations of this study
▪ This is the first study to compare two inter-
nationally accepted definitions in categorising
patients with catheter-associated urinary tract
infections, namely the Health Protection Agency
and Centers for Disease Control and Prevention
definitions.
▪ This study demonstrates the feasibility of con-
ducting point prevalence surveys of
healthcare-associated urinary tract infections in a
standardised manner to facilitate comparisons
over time within individual health facilities.
▪ A limitation of this study is that the survey was
conducted in only six hospitals within two states
and territories limiting the generalisability of the
results. However, there were significant findings
enabling recommendations for a future national
point prevalence study to be made.
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However, these infections are a potentially preventable
adverse event rather than an unpredictable complication
and it is possible to significantly reduce the rate of HAIs
through effective infection prevention and control.6
HAIs could be prevented by sustained, multifaceted
infection prevention and control programmes, including
the Hawthorne effect of surveillance.4 Although pro-
spective active surveillance is considered to be the gold
standard for surveillance, prevalence surveys are quite
useful as they can provide baseline information about
the occurrence and distribution of HAI, are generally
easy to conduct, relatively inexpensive and not too time
consuming.7 8 National surveillance of HAI has been
introduced in North America and in many European
countries, and national prevalence surveys of HAI are
also increasingly common.8
Urinary tract infections (UTIs) account for more than
30% of HAIs reported by acute care hospitals.9 Virtually
all healthcare-associated UTIs (HAUTIs) are caused by
instrumentation of the urinary tract with 80% traced to
the use of indwelling urinary catheters.10 The use of
urethral catheters is very common with 15–25% of hospi-
talised patients receiving a short-term indwelling urinary
catheter, hence high HAUTI rates are not surpris-
ing.11–14 Calculation of how many catheter-associated
UTIs (CAUTIs) may be preventable varies considerably
with estimates from unpublished data ranging from 17%
to 69%.15 Given recommended infection control mea-
sures, up to 380 000 infections and 9000 deaths related
to CAUTIs per year could be prevented in the USA.15
Unlike other countries, Australia has not recently con-
ducted a national point prevalence study on HAIs. The
last Australian national prevalence survey for nosocomial
and community-acquired infections was conducted in
1984,16 with authors reporting a prevalence of 6.3% for
HAIs with UTIs contributing to 22% of infections.16 The
most recent study to report the incidence of UTIs in
Australia was conducted in two hospitals, with authors
reporting an incidence of 1.66%.17
To date, in Australia there is no specific national strat-
egy and surveillance system in place to address HAUTIs
and CAUTIs.18 19 Several Australian States undertake
surveillance activities for HAIs including the Victorian
Hospital Acquired Surveillance Programme (VICNISS);
South Australian Infection Control Service (SANIT); the
Centre for Healthcare Related Infection Surveillance
and Prevention (CHRISP) in Queensland18 20; the
Tasmanian Infection Prevention and Control Unit
(TIPCU) and the Hospital Infection Surveillance
program in Western Australia (HISWA). These surveil-
lance programmes differ considerably, with variability in
infections surveyed and level of participation by hospitals
with no mandatory participation required for hospitals
within these states except New South Wales.21 At
present, there is no national or state level surveillance
for HAUTIs in Australian hospitals.
To provide the foundation for a national point preva-
lence study and for a future prospective interventional
study, we conducted a preliminary study in six Australian
hospitals. The aims and objectives of this study were to
(1) establish the point prevalence of HAUTIs and
CAUTIs, (2) describe level and comprehensiveness of
documentation related to care of urinary catheters,
(3) compare two internationally accepted definitions in
categorising patients with CAUTIs, namely the Health
Protection Agency (HPA)22 and Centers for Disease
Control and Prevention (CDC)23 definitions and
(4) compare the sensitivity of microbiology laboratory
data, coding data and clinical record documentation at
identifying cases of HAUTIs and CAUTIs. It is expected
that the findings from this study will provide policy-
makers and healthcare providers in Australia with
HAUTI data to inform the development and implemen-
tation of targeted surveillance and high-impact HAUTI
prevention programmes, as well as testing a process for
point prevalence of HAUTI.
METHODS
Study design
Cross-sectional study.
Setting and data sources/measurement
Three publicly funded and three private hospitals in two
Australian jurisdictions participated in the PPS. Two of
the three publicly funded hospitals had greater than 400
beds each and similar case mix which included intensive
care unit, 24 h emergency department, haematology/
oncology units, dialysis units, paediatrics/women and
children, elective and emergency surgery. The third
public hospital had fewer than 400 beds and no paediat-
ric or dialysis services. One private hospital was a
rehabilitation hospital and the other two provided acute
medical and surgical services.
The survey was conducted over the first 6 months of
2013 in two phases. The first phase involved two public
and two private hospitals and the data were collected
concurrently over a single day at these sites. The second
phase of the study was conducted in the remaining
private and public hospital after additional funding had
been obtained. Similar to phase 1, patient records were
concurrently surveyed at both sites.
For each hospital, the survey was conducted using a
standardised paper-based questionnaire developed by
the researchers from the CAUTI toolkit resources of the
CDC.24 On the day of the point prevalence study, demo-
graphic and clinical data were obtained from patients’
notes and laboratory records. Data collected included
age, sex, ward specialty, presence of urinary catheter and
documentation of insertion and causative organism
where appropriate of all eligible patients. For each
patient who had a catheter inserted, documentation was
reviewed to determine whether the need for the cath-
eter was assessed daily, consistent with best practice
recommendations.25 26 A separate protocol paper pro-
vides more details of the study methods.27
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The DRG (Diagnosis-Related Group) and ICD-10
(International Classification of Diseases Tenth revision)
coding data were retrieved by the medical records
departments approximately 2 months after completion
of the PPS. Data from the standardised paper-based
questionnaires were subsequently entered into a
purpose designed Excel database and exported into a
statistical software package for analysis.
Participants
Records of patients of all ages, hospitalised on the day of
the point prevalence at the study sites, were eligible for
inclusion, with some exceptions. Outpatients, patients in
adult mental health units, patients categorised as main-
tenance care type (ie, patients waiting to be transferred
to a long-term care facility) and those in the emergency
department during the duration of the survey were
excluded.
Bias
Inter-rater reliability was enhanced by development and
use of a standardised training programme, with mastery
being formally assessed prior to data collection, to
reduce the possibility of information bias.27 The data
were collected by trained research assistants who were all
registered or enrolled nurses. Before the survey dates, all
research assistants were provided with a training package
and underwent 2 h of mandatory face-to-face training
and assessment to assist them in collecting point preva-
lence data and to enhance inter-rater reliability in the
application of HAUTI and CAUTI definitions and other
survey procedures. The training package and pro-
gramme were developed using the Health Protection
Scotland Education and Training Events resources.28
Study size
All hospitalised persons in the participating organisation
who met eligibility criteria on a given day were included
in the study.
Variables
The main outcome measure was HAUTIs with CAUTI
being specifically identified within this outcome. HAI
status was defined as hospitalisation greater than 48 h.
HAUTIs and CAUTIs were ascertained by using two sets
of criteria, those established by the HPA/European
Centre for Disease Prevention and Control22 and by the
CDC.23 These definitions are complex; therefore, flow
diagrams (available as online supplementary material)
were provided to research assistants’ to assist them with
case definitions.27
All patients were ascribed one or more diagnosis-
related codes on discharge from hospital. These codes
are known as the Australian Refined DRGs. This classifi-
cation system enables a hospital’s case mix to be
described in a clinically meaningful way, enables subse-
quent use to identify resources required by the hospital
and forms the basis for funding in some Australian
States and Territories.29 Our study collected ICD-10
codes for infection and ICD-10 Clinical Modification for
procedures30 to identify those relevant to UTIs and
catheterisation.
Statistical methods
Data analysis was performed using IBM Statistics SPSS
V.20. Descriptive analysis such as counts and percentages
for categorical data and measures of central tendency
and dispersion for continuous data was performed. The
HAUTI and CAUTI point prevalences were calculated
using the total patient population surveyed as the
denominator. The sensitivity and positive predictive
values of CDC and HPA surveillance definitions for
HAUTI and CAUTI were compared. Cross tabulation
and measures of association were applied using χ2 tests
and Fishers exact test where appropriate to explore dif-
ferences between public and private hospitals and
factors significantly associated with HAUTI and CAUTI.
RESULTS
A total of six hospitals were surveyed over a 6-month
period and all data have been aggregated. Subgroup
analysis is limited to public and private hospital status to
prevent potential identification of individual participat-
ing institutions.
Participants
A total of 1109 patients were surveyed on the designated
days. Of these, 505 (45.5%) were men and 604 (54.5%)
were women. The median age was 64 years (IQR 42–
79 years). Table 1 shows the results stratified by hospital
type with 905 patients surveyed from the three public
hospitals and 204 from the three private hospitals. The
case mix of patients based on the DRG data varied
across public and private hospitals with the majority of
patients managed for diseases of the musculoskeletal
system and connective tissue. This DRG was followed by
diseases of the digestive system for the private hospitals
and patients assigned codes based on factors influencing
health status and other contacts with health services for
the public hospitals such as patients attending follow-up
visits and organ donors (table 1).
Prevalence of UTI
The overall prevalence of HAUTI was 1.4% (15/1109)
and the prevalence of CAUTI was 0.9% (10).
Staphylococcus aureus (20%) and Candida species (20%)
were the most common pathogens identified among the
patients with HAUTIs. Table 2 presents the microbial
characteristics of all infections. Of the 1109 patients who
were included in the survey, 1.1% met the CDC surveil-
lance criteria for symptomatic UTI and 0.2% met the
CDC criteria for asymptomatic UTI. One per cent of the
patients met the microbiological HPA criteria and 0.2%
the non-microbiological HPA criteria. There was one
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Table 1 Patient demographics
Characteristic
Private
hospitals
n (%)
n=204
Public
hospitals
n (%)
n=905
Total (%)
N=1109
Age category (in years)
<35 21 (10.3) 210 (23.2) 231 (20.8)
35–64 46 (22.5) 292 (32.3) 338 (30.5)
65–84 82 (40.2) 299 (33.0) 381 (34.4)
≥85 55 (27.0) 104 (11.5) 159 (14.3)
Gender
Male 79 (38.7) 426 (47.1) 505 (45.5)
Female 125 (61.3) 479 (52.9) 604 (54.5)
Ward specialty
Surgery 69 (33.8) 300 (33.1) 369 (33.3)
General medicine 55 (27.0) 273 (30.2) 328 (29.6)
General practice/rehabilitation/geriatric medicine 37 (18.1) 100 (11.0) 137 (12.4)
Obstetrics/gynaecology 17 (8.3) 86 (9.5) 103 (9.3)
Oncology 17 (8.3) 55 (6.1) 72 (6.5)
Paediatrics 7 (3.4) 63 (7.0) 70 (6.3)
High dependency unit 0 (0) 28 (3.1) 28 (2.5)
Other (pain management) 2 (1.0) 0 (0) 2 (0.2)
DRG
Diseases of the musculoskeletal system and connective tissue 41 (20.1) 130 (14.4) 171 (15.4)
Factors influencing health status and other contacts with health services 5 (2.5) 89 (9.8) 94 (8.5)
Diseases of the digestive system 18 (8.8) 63 (7.0) 81 (7.3)
Diseases of the circulatory system 8 (3.9) 65 (7.2) 73 (6.6)
Diseases of the respiratory system 14 (6.9) 47 (5.2) 61 (5.5)
Pregnancy, childbirth and puerperium 11 (5.4) 47 (5.2) 58 (5.2)
Diseases of the nervous system 15 (7.4) 39 (4.3) 54 (4.9)
Newborns and other neonates 16 (7.8) 27 (3.0) 43 (3.9)
Major procedures where the principal diagnosis may be associated with
any major diagnostic category
16 (7.8) 18 (2.0) 34 (3.1)
Diseases of the kidney and urinary tract 8 (3.9) 25 (2.8) 33 (3.0)
Other* 38 (18.6) 133 (14.7) 171 (15.4)
Missing† 14 (6.9) 222 (24.5) 236 (21.3)
*Diseases of the skin, subcutaneous tissue and breast; injuries, poisoning and toxic effects of drugs; diseases of the hepatobiliary system and
pancreas; neoplastic diseases (haematological and solid neoplasms); infectious and parasitic diseases; endocrine, nutritional and metabolic
diseases and disorders; diseases of the ear, nose, mouth and throat; diseases of the female reproductive system; diseases of the male
reproductive system; mental diseases and disorders; diseases of the blood and blood forming organs and immunological diseases; diseases
of the eye; burns.
†Missing DRG data include all patients in one public hospital.
DRG, Diagnosis-Related Group.
Table 2 Microbial characteristics for non-CAUTI HAUTIs and CAUTIs
Type of organism
Non-CAUTI
N=5
ICD-10 code
yes/no
CAUTI
N=10
ICD code
yes/no
TOTAL
N=15
Gram positive
Enterococcus species 1 No 1 No 2
Staphylococcus aureus 1 Yes 2 1 yes 1 no 3
Gram negative
Escherichia coli 0 NA 2 Yes 2
Klebsiella species 0 NA 1 No 1
Proteus species 2 No 0 NA 2
Pseudomonas species 1 No 0 NA 1
Fungi
Candida species 0 NA 3 1 yes 2 no 3
Organism not listed 0 NA 1 Yes 1
CAUTI, catheter-associated urinary tract infection; HAUTI, healthcare-associated urinary tract infection; ICD, International Classification of
Diseases; NA, not applicable.
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patient who had microbiological and non-
microbiological HPA confirmation of UTI.
Tables 3 and 4 provide the comparison of surveillance
definitions, the positive predictive value and sensitivity
with the HPA definition classified as the ‘test’ and the
CDC definition as the ‘gold standard’.
Pattern of catheter usage
One-quarter (26.3%) of all surveyed patients had a
urinary catheter in place during the audit admission with
the majority being indwelling catheters (88.7%). Less
than half of patients surveyed had appropriate documen-
tation, such as designation of person inserting catheter
(28.8%) and reason for insertion (38.7%; table 5). For
patients with a catheter who had the reason for insertion
stated that the majority of catheters were inserted for
perioperative use for selective surgical procedures
(38.9%), acute urinary retention (24.8%) and urinary
output monitoring in critically ill patients (22.1%).
Of the 292 patients who had a catheter in during the
audit only 7 (2.4%) patients were assigned ICD-10 codes
by the medical records department as having a urinary
catheter with 2 (0.7%) coded as having a ‘bladder cath-
eter’ during their admission.
ICD-10 codes
Eighty-six (7.8%) patients were coded by the medical
records department as having a UTI. This coding did
not take into account whether they were healthcare asso-
ciated or not. Eight of the 15 patients who were
ascertained to have a HAUTI based on the CDC and
HPA criteria (with 6 of these being CAUTI) were also
coded by the medical records department with an
ICD-10 code for UTI diagnosis.
DISCUSSION
There were four main findings from this study: the point
prevalence of HAUTI was comparable to other studies;
identification of poor standards of documentation; a
suggestion that the CDC surveillance definition identi-
fied more patients with HAUTI compared with the HPA
and that clinical coding data grossly underestimates the
incidence of HAUTI. Each of these findings will now be
explored in more detail.
The 1.4% HAUTI point prevalence and 0.9% CAUTI
point prevalence for this study are consistent with previ-
ously published reported rates, nationally17 and inter-
nationally.31 While this prevalence may seem low,
approximately 20–30% of all HAIs are UTIs.31 32
Extrapolating our data, we estimate that on any given
day, there are approximately 1120 Australian inpatients
with a HAUTI, assuming 80 000 acute hospital beds in
Australia.33 In addition, a proportion of bacteraemias
are associated with UTIs and these have an associated
mortality.34–36 In the era of increasing antimicrobial
resistance, particularly in Gram-negative organisms,
patient outcomes have the potential to worsen, demon-
strating a growing need for vigilance in infection preven-
tion and HAUTI surveillance.
In this study, documentation relating to catheter inser-
tion and management in all healthcare facilities in the
study was poor. There are two main implications that
follow from this—evidence-based practice and health
economics. For evidence-based practice, the lack of
documentation about who inserted catheter, catheter
type and reasons for insertion would not inspire confi-
dence in patients about the quality of care provided or
compliance with evidence-based practice. For example,
our survey evaluated documentation against national
and international practice recommendations such as
whether the ongoing need for a catheter is regularly
reviewed.9 25 26 The biggest risk for UTI is duration of
indwelling urinary catheter.9 While it is reasonable to
assume that the need for the catheter was regularly
renewed for some patients and simply not documented,
it is also probable that review of the need for catheter
was not undertaken for many. Minimising the number
of patients with catheters and the duration of catheter-
isation could significantly reduce the incidence of UTIs
and HAIs more generally.25 We have identified a poten-
tial gap in best practice which lends itself to future pro-
spective interventional studies targeting improvements
in urinary catheter care. We identified a further issue
with poor documentation as less than 10% of urinary
catheter usage was identified by ICD-10 coding. This has
potential implications for funding, depending on the
funding model applied.
Table 3 Comparison of Centers for Disease Control and
Prevention (CDC) and Health Protection Agency (HPA)
surveillance definitions
CDC*
positive
CDC
negative Total
HPA positive 11 (1.0%) 1 (0.1%) 12 (1.1%)
HPA negative 3 (0.3%) 1094 (98.6) 1097 (98.9%)
Total 14 (1.3%) 1095 (98.7%) 1109 (100.0%)
The percentages represent the number of people identified as
having a healthcare-associated urinary tract infection based on a
specific criteria divided by the total number of people surveyed.
*For the purposes of calculation, the CDC definition was
considered to be gold standard.
Table 4 Estimates of the positive predictive value,
sensitivity and CIs of the Health Protection Agency
surveillance definition compared with the Centers for
Disease Control and Prevention definition
Result Value (%) CI
Sensitivity 78.57 (52.41 to 92.43)
Specificity 99.91 (99.48 to 99.98)
Positive predictive value 91.67 (64.61 to 98.51)
Negative predictive value 99.73 (99.20 to 99.91)
Diagnostic accuracy 99.64 (99.08 to 99.86)
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In this study, the CDC surveillance definition identi-
fied more patients with HAUTI than the HPA definition.
The difference in positive predictive value, however, was
not statistically significant. Research assistants
responsible for data collection overwhelmingly reported
that the HPA definition was easier to use. Therefore,
while the CDC definition is recognised as the gold stand-
ard,37 and HPA in our study had a lower capture rate,
Table 5 Catheter information
Characteristic
Private hospitals (%)
n=60
Public hospitals (%)
n=232
Total (%)
N=292
Catheter at any time during this admission
Yes 60 (29.4) 232 (25.6) 292 (26.3)
No 144 (70.6) 673 (74.4) 817 (73.7)
Presence of catheter
Currently in situ 29 (48.3) 146 (62.9)* 175 (59.9)
Catheter inserted but removed during admission 31 (51.7) 85 (36.7) 116 (39.7)
Intermittent 0 (0) 1 (0.4) 1 (0.4)
Catheter location
Indwelling 54 (90.0) 205 (88.4) 259 (88.7)
Supra pubic 4 (6.6) 10 (4.3) 14 (4.8)
Intermittent 0 (0) 2 (0.9) 2 (0.7)
Both indwelling and supra pubic 1 (1.7) 0 (0) 1 (0.3)
Not documented 1 (1.7) 15 (6.4) 16 (5.5)
Catheter type
Silver alloy 0 (0) 1 (0.4) 1 (0.3)
Silicone 7 (11.7) 55 (23.7) 62 (21.2)
Antimicrobial 0 (0) 0 (0) 0 (0)
Foley 0 (0) 19 (8.2) 19 (6.5)
Latex 0 (0) 2 (0.9) 2 (0.7)
Other 0 (0) 11 (7.8) 11 (3.8)
Not documented 53 (88.3) 144 (62.1) 197 (67.5)
Catheter size (French grade)
6 0 (0) 1 (0.4) 1 (0.3)
10 0 (0) 1 (0.4) 1 (0.3)
12 16 (26.7) 16 (6.9) 32 (11.0)
14 10 (16.7) 54 (23.3) 64 (22.0)
16 8 (13.3) 19 (8.2) 27 (9.2)
18 0 (0) 3 (1.3) 3 (1.0)
20 2 (3.3) 2 (0.9) 4 (1.4)
22 0 (0) 1 (0.4) 1 (0.3)
24 1 (1.7)† 0 (0) 1 (0.3)
Not documented 24 (40.0) 135 (58.2) 159 (54.5)
Inserted by
Nurse 5 (8.3) 46 (19.8) 51 (17.5)
Doctor 13 (21.7) 18 (7.8) 31 (10.6)
Other (student) 1 (1.7) 1 (0.4) 2 (0.7)
Not documented 41 (68.3) 167 (72.0) 208 (71.2)
Reason for insertion stated
Yes 36 (60.0) 77 (33.2) 113 (38.7)
No 24 (40.0) 155 (66.8) 179 (61.3)
Cleaning solution
Chlorhexidine 0 (0) 1 (0.4) 1 (0.3)
Unknown 60 (100) 231 (99.6) 291 (99.7)
Ongoing need for catheter reviewed (days)
0 34 (56.7) 157 (67.7) 191 (65.4)
1 10 (16.7) 35 (15.1) 45 (15.4)
2–3 5 (8.3) 24 (10.3) 29 (9.9)
4–5 1 (1.7) 3 (1.3) 4 (1.4)
>5 0 (0) 3 (1.3) 3 (1.0)
Not documented 10 (16.7) 10 (4.3) 20 (6.8)
*It is unknown if catheter still in situ for three of these participants at time of survey.
†One patient had both indwelling and supra pubic catheters of two different sizes.
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use of the HPA definition is still likely to predict 91.7%
(CI 64.6% to 98.5%) of infections diagnosed through
use of the CDC definition. Therefore, given the much
greater ease of use of the HPA definition, we recom-
mend the use of the HPA definition in future point
prevalence studies. Any potential issue of underestimat-
ing the incidence of HAUTI using the HPA surveillance
definition is less important where data are used in a
quality improvement framework, as these data can be
used to inform and evaluate interventions38 rather than
for diagnostic purposes or for performance manage-
ment (ie, trends overtime being most important). Other
authors have commented that prospective UTI surveil-
lance is costly and time consuming to conduct39 40;
therefore, we explored alternatives to prospective UTI
surveillance by comparing our prevalence data with post-
discharge coding data. Australian coding data do not dis-
tinguish between HAI cases and non-HAI cases. This is
unlike the US coding data which provide a present on
admission indicator code to inpatients helping to iden-
tify hospital-acquired infections.41 In our study, ICD
coding missed 50% of HAUTIs. If ICD-10 codings are
used to determine the incidence of HAUTI, for report-
ing purposes our study suggests that such a method will
grossly underestimate the number of infections, with
implications for funding arrangements. This finding has
also been found for other infections.42
RECOMMENDATIONS FOR PRACTICE, POLICY AND
RESEARCH
To enable the reduction of HAIs related to the genito-
urinary tract, it is important that all healthcare facilities
have appropriate policies and protocols for insertion of
either a urethral or supra pubic catheter. It is important
that these policies and protocols are evidence based.
However, prior to inserting a catheter, the question of
whether the patient requires this procedure should be
raised. If the decision is made to insert a catheter, then
consideration should be given to the size of the catheter
to insert, the reason for the insertion and duration of
time that the catheter will be in place to allow timely
removal of the catheter. All information relating to the
catheter and its care should also be documented in the
notes (this could be in the form of a sticker to be easily
found in the notes) and on the care plan.
Documentation by medical and nursing staff is import-
ant for the day-to-day infection prevention and control
and to alert staff to ensure timely removal of urinary
catheters. If a CAUTI is diagnosed then documentation
should include: causative organism, what antibiotics
have been started and whether the antibiotics are appro-
priate to treat that microorganism. Other relevant notes
are actions taken, such as removal or replacement of the
catheter. One potential way of improving compliance
with clinical guidelines and documentation at the inser-
tion and maintenance phases of catheter care is the use
of a checklist or ‘bundle’ approach.43
To improve health outcomes for patients, it is important
to continue exploration of ways to identify and reduce
HAUTIs and CAUTIs. We have shown it is feasible to
conduct prevalence studies across six health institutions,
and funding should be sought for a national point preva-
lence of UTIs as demonstrated by countries already under-
taking this.4 Analysing national point prevalence data will
provide a baseline for intervention studies that test care
bundles to reduce HAUTIs and their sequelae.43
Currently, it appears that ICD-10 coding is not a reliable
way of monitoring prevalence of HAUTI, at least in some
healthcare facilities. Our findings were consistent with
other HAI coding.42 This potential under-reporting of
infections has implications for policy and healthcare reim-
bursement, although in some US jurisdictions, healthcare
facilities are penalised for HAIs rather than being reim-
bursed.44 45 We recommend that facilities undertake
audits to compare clinical and coding data periodically.
There are some limitations in our study. The survey was
conducted in only six hospitals within two states and terri-
tories limiting the generalisability of the results. However,
there were significant findings enabling recommendations
for a future national point prevalence study to be made.
Another limitation of our study is the reliance on clinical
records and not direct diagnosis. This was overcome by
using research assistants with some prior clinical and infec-
tion control knowledge, for example, registered nurses,
for data collection. The research assistants were adequately
trained and the outcome of the training was evaluated by
post training case study assessments.27 Such a process also
enhanced inter-rater reliability. There were no previous
HAUTI and CAUTI rates for comparison within the study
sites as they had not collected this type of data before. As
earlier stated, the findings can now be used to make
recommendations for conducting PPS in a standardised
manner to facilitate comparisons over time within individ-
ual health facilities. The aggregation of data from all par-
ticipating hospitals for analysis may be a further limitation.
The size and scope of services in these hospitals varies and
this in turn presents variations in risk. Regardless, the
process we employed is common in point prevalence
studies, which only capture data at a specific point in
time.8 9 Despite the study limitations, this survey has identi-
fied some priority areas including efficacy of documenta-
tion practices related to care of urinary catheters which
are key to preventing CAUTIs. There were also no obvious
sources of bias.
CONCLUSION
To tackle the issue of CAUTIs and other HAIs in
Australia, it is imperative to develop a national surveil-
lance system based on validated methods and definitions
which have been found to be effective in other devel-
oped countries. This study provides a foundation for the
development of a national infection control initiative in
our rapidly evolving healthcare environment and asso-
ciated challenges with drug resistance.
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